These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 25103325)
1. Physiologically based pharmacokinetic modeling of impaired carboxylesterase-1 activity: effects on oseltamivir disposition. Hu ZY; Edginton AN; Laizure SC; Parker RB Clin Pharmacokinet; 2014 Sep; 53(9):825-36. PubMed ID: 25103325 [TBL] [Abstract][Full Text] [Related]
2. Effects of alcohol on human carboxylesterase drug metabolism. Parker RB; Hu ZY; Meibohm B; Laizure SC Clin Pharmacokinet; 2015 Jun; 54(6):627-38. PubMed ID: 25511794 [TBL] [Abstract][Full Text] [Related]
3. Association of Oseltamivir Activation with Gender and Carboxylesterase 1 Genetic Polymorphisms. Shi J; Wang X; Eyler RF; Liang Y; Liu L; Mueller BA; Zhu HJ Basic Clin Pharmacol Toxicol; 2016 Dec; 119(6):555-561. PubMed ID: 27228223 [TBL] [Abstract][Full Text] [Related]
4. Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants. Parrott N; Davies B; Hoffmann G; Koerner A; Lave T; Prinssen E; Theogaraj E; Singer T Clin Pharmacokinet; 2011 Sep; 50(9):613-23. PubMed ID: 21827216 [TBL] [Abstract][Full Text] [Related]
5. Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans. Tarkiainen EK; Backman JT; Neuvonen M; Neuvonen PJ; Schwab M; Niemi M Clin Pharmacol Ther; 2012 Jul; 92(1):68-71. PubMed ID: 22588607 [TBL] [Abstract][Full Text] [Related]
6. Age-Dependent Absolute Abundance of Hepatic Carboxylesterases (CES1 and CES2) by LC-MS/MS Proteomics: Application to PBPK Modeling of Oseltamivir In Vivo Pharmacokinetics in Infants. Boberg M; Vrana M; Mehrotra A; Pearce RE; Gaedigk A; Bhatt DK; Leeder JS; Prasad B Drug Metab Dispos; 2017 Feb; 45(2):216-223. PubMed ID: 27895113 [TBL] [Abstract][Full Text] [Related]
7. Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants. Zhu HJ; Markowitz JS Drug Metab Dispos; 2009 Feb; 37(2):264-7. PubMed ID: 19022936 [TBL] [Abstract][Full Text] [Related]
8. Simulation of the Pharmacokinetics of Oseltamivir and Its Active Metabolite in Normal Populations and Patients with Hepatic Cirrhosis Using Physiologically Based Pharmacokinetic Modeling. Chen Y; Ke M; Xu J; Lin C AAPS PharmSciTech; 2020 Mar; 21(3):98. PubMed ID: 32128656 [TBL] [Abstract][Full Text] [Related]
9. The effect of carboxylesterase 1 (CES1) polymorphisms on the pharmacokinetics of oseltamivir in humans. Suzaki Y; Uemura N; Takada M; Ohyama T; Itohda A; Morimoto T; Imai H; Hamasaki H; Inano A; Hosokawa M; Tateishi M; Ohashi K Eur J Clin Pharmacol; 2013 Jan; 69(1):21-30. PubMed ID: 22673926 [TBL] [Abstract][Full Text] [Related]
10. The novel carboxylesterase 1 variant c.662A>G may decrease the bioactivation of oseltamivir in humans. Oh J; Lee S; Lee H; Cho JY; Yoon SH; Jang IJ; Yu KS; Lim KS PLoS One; 2017; 12(4):e0176320. PubMed ID: 28437488 [TBL] [Abstract][Full Text] [Related]
14. A simple allele-specific polymerase chain reaction method to detect the Gly143Glu polymorphism in the human carboxylesterase 1 gene: importance of genotyping for pharmacogenetic treatment. Walter Soria N; Belaus A; Galván C; Ana Pasquali M; Velez P; Del Carmen Montes C; Beltramo DM Genet Test Mol Biomarkers; 2010 Dec; 14(6):749-51. PubMed ID: 20858053 [TBL] [Abstract][Full Text] [Related]
15. Natural Products as Modulators of CES1 Activity. Qian Y; Markowitz JS Drug Metab Dispos; 2020 Oct; 48(10):993-1007. PubMed ID: 32591414 [TBL] [Abstract][Full Text] [Related]
16. Surge in expression of carboxylesterase 1 during the post-neonatal stage enables a rapid gain of the capacity to activate the anti-influenza prodrug oseltamivir. Shi D; Yang D; Prinssen EP; Davies BE; Yan B J Infect Dis; 2011 Apr; 203(7):937-42. PubMed ID: 21402544 [TBL] [Abstract][Full Text] [Related]
17. Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender. Shi J; Wang X; Nguyen JH; Bleske BE; Liang Y; Liu L; Zhu HJ Biochem Pharmacol; 2016 Nov; 119():76-84. PubMed ID: 27614009 [TBL] [Abstract][Full Text] [Related]
18. Simultaneously Predicting the Pharmacokinetics of CES1-Metabolized Drugs and Their Metabolites Using Physiologically Based Pharmacokinetic Model in Cirrhosis Subjects. Luo X; Zhang Z; Mu R; Hu G; Liu L; Liu X Pharmaceutics; 2024 Feb; 16(2):. PubMed ID: 38399287 [TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of oseltamivir in non-pregnant and pregnant women. Pillai VC; Han K; Beigi RH; Hankins GD; Clark S; Hebert MF; Easterling TR; Zajicek A; Ren Z; Caritis SN; Venkataramanan R Br J Clin Pharmacol; 2015 Nov; 80(5):1042-50. PubMed ID: 26040405 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of carboxylesterase-1 alters clopidogrel metabolism and disposition. Laizure SC; Hu ZY; Potter PM; Parker RB Xenobiotica; 2020 Mar; 50(3):245-251. PubMed ID: 31039046 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]